Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis

• Published in: BMJ open gastroenterology 2021-03, Vol.8 (1), p.e000571
• Main Authors: Shehab, Mohammad, Alrashed, Fatema, Shuaibi, Sameera, Alajmi, Dhuha, Barkun, Alan
• Format: Article
• Language: English
• Subjects: Abdomen; Anorexia; Asymptomatic; Bias; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - mortality; Critical Care - statistics & numerical data; Diarrhea; Disease transmission; Editorials; Enzymes; Epidemiology; Fatalities; Gastrointestinal Diseases - epidemiology; Gastrointestinal Diseases - mortality; Gastrointestinal Diseases - virology; Hospitalization - statistics & numerical data; Humans; Intensive care; Laboratories; Liver; Liver - enzymology; Liver Diseases - epidemiology; Liver Diseases - mortality; Liver Diseases - virology; Meta-analysis; Mortality; Nausea; Pain; Pandemics; Patients; Prevalence; Respiratory diseases; SARS-CoV-2; Sensitivity analysis; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Systematic review; Vomiting
• ISSN: 2054-4774; 2054-4774
• DOI: 10.1136/bmjgast-2020-000571

Background and aimsPatients infected with the SARS-CoV-2 usually report fever and respiratory symptoms. However, multiple gastrointestinal (GI) manifestations such as diarrhoea and abdominal pain have been described. The aim of this study was to evaluate the prevalence of GI symptoms, elevated liver enzymes and mortality of patients with COVID-19.MethodsA systematic review and meta-analysis of published studies that included a cohort of patients infected with SARS-CoV-2 were performed from 1 December 2019 to 15 December 2020. Data were collected by conducting a literature search using PubMed, Embase, Scopus, and Cochrane according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We analysed pooled data on the prevalence of individual GI symptoms and elevated liver enzymes and performed subanalyses to investigate the relationship between GI symptoms/elevated liver enzymes, geographical location, mortality, and intensive care unit (ICU) admission.ResultsThe available data of 78 798 patients positive for SARS-CoV-2 from 158 studies were included in our analysis. The most frequent manifestations were diarrhoea (16.5%, 95% CI 14.2% to 18.4%), nausea (9.7%, 95% CI 9.0% to 13.2%) and elevated liver enzymes (5.6%, 95% CI 4.2% to 9.1%). The overall mortality and GI mortality were 23.5% (95% CI 21.2% to 26.1%) and 3.5% (95% CI 3.1% to 6.2%), respectively. Subgroup analysis showed non-statistically significant associations between GI symptoms/elevated liver enzymes and ICU admissions (OR=1.01, 95% CI 0.55 to 1.83). The GI mortality was 0.9% (95% CI 0.5% to 2.2%) in China and 10.8% (95% CI 7.8% to 11.3%) in the USA.ConclusionGI symptoms/elevated liver enzymes are common in patients with COVID-19. Our subanalyses showed that the presence of GI symptoms/elevated liver enzymes does not appear to affect mortality or ICU admission rate. Furthermore, the proportion of GI mortality among patients infected with SARS-CoV-2 varied based on geographical location.